<code id='499CC5F4EC'></code><style id='499CC5F4EC'></style>
    • <acronym id='499CC5F4EC'></acronym>
      <center id='499CC5F4EC'><center id='499CC5F4EC'><tfoot id='499CC5F4EC'></tfoot></center><abbr id='499CC5F4EC'><dir id='499CC5F4EC'><tfoot id='499CC5F4EC'></tfoot><noframes id='499CC5F4EC'>

    • <optgroup id='499CC5F4EC'><strike id='499CC5F4EC'><sup id='499CC5F4EC'></sup></strike><code id='499CC5F4EC'></code></optgroup>
        1. <b id='499CC5F4EC'><label id='499CC5F4EC'><select id='499CC5F4EC'><dt id='499CC5F4EC'><span id='499CC5F4EC'></span></dt></select></label></b><u id='499CC5F4EC'></u>
          <i id='499CC5F4EC'><strike id='499CC5F4EC'><tt id='499CC5F4EC'><pre id='499CC5F4EC'></pre></tt></strike></i>

          focus

          focus

          author:focus    Page View:67
          Erik Tokat -- biotech JPM coverage from STAT
          Eric Tokat is co-president of investment banking at Centerview Partners. Courtesy Centerview Partners

          SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years.

          That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech. Last year, Tokat’s advisory firm, Centerview Partners, was involved in 19 of the 23 biotech transactions valued at $1 billion or more. Two more acquisitions of Centerview clients — Harpoon Therapeutics and Ambrx Biopharma — were announced Monday morning.

          advertisement

          “I’m not sure if we’re going to have 23 deals or 25 deals, but I think it’s going to be a good year,” said Tokat, speaking to STAT over coffee on the sidelines of the J.P. Morgan Healthcare Conference.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          OTC birth control: A brief history of over the counter pill design
          OTC birth control: A brief history of over the counter pill design

          Illustration:AlexHogan/STAT;Photo:CourtesyPerrigoIt’snoteverydaythatamarketingteamistaskedwithdesign

          read more
          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more

          Study: Spinal cord stimulation helps patients with paralysis walk again

          GrégoireCourtineadvisesDavid,apatient.Courtine’slatestresearchpapersuggestspersonalizedelectricalsti